Protagonist Therapeutics Announces Equity Inducement Award

On April 16, 2025, Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced it had issued an equity inducement award. This was granted on April 15 to a new employee, aligning with the terms of their employment offer. The award includes options to purchase 20,000 shares of the company's common stock at the price of $46.95, which matches the closing stock price on the Nasdaq on the grant date.

The granted options are part of the Amended and Restated 2018 Inducement Plan. These options will become fully vested over four years, with a quarter vesting after one year and the remainder in monthly increments for the following three years. The Compensation Committee of the Board of Directors approved this as a material inducement under Nasdaq Marketplace Rule 5635(c)(4).